title: Neurite outgrowth of striatal neurons in vitro: involvement of purines in the growth-promoting effect of myenteric plexus explants.
abstract: We have shown previously that a soluble factor(s) released by the myenteric plexus promotes neurite outgrowth from postnatal striatal neurons, and that this effect was abolished by tetrodotoxin. We have now investigated the possible involvement of purines in the mediation of this neuritogenic response, by examining their effect on neurite length of striatal neurons both in co-culture with myenteric plexus explants and cultured alone. Both ATP and 2-chloroadenosine partially reversed the inhibitory effect of tetrodotoxin in co-cultures with whole myenteric plexus, while the stable ATP analogue, alpha, beta-methylene ATP, had no effect, suggesting that ATP was being broken down to adenosine before exerting its action. Further support for this view was that the ATP (P2) purinoceptor antagonist suramin did not reverse the effects of ATP, while the adenosine (P1) purinoceptor antagonist 8-(p-sulphophenyl)theophylline did antagonize the effects of ATP in tetrodotoxin-treated co-cultures. Further, both 8-(p-sulphophenyl)theophylline and adenosine deaminase reduced the effect of the myenteric plexus on striatal neurons in the absence of tetrodotoxin, and the adenylate cyclase activator forskolin completely reversed the effect of tetrodotoxin in our co-culture system. The neurite outgrowth-promoting effect of 2-chloroadenosine in tetrodotoxin-treated co-cultures was not further enhanced by a combination of neuropeptides. Serotonin and GTP were without effect on striatal neurons in the presence or absence of myenteric plexus explants. In experiments without myenteric plexus, both 2-chloroadenosine and forskolin caused a slight increase in striatal neurite length; ATP and GTP were ineffective. Basic fibroblast growth factor, nerve growth factor, neurotrophin-3 or neurotrophin-4/5 had no effect on neurite outgrowth in postnatal striatal cultures after two days in vitro. When these growth factors were added in combination with 2-chloroadenosine, the observed increase in mean neurite length did not exceed that induced by 2-chloroadenosine alone. Both 2-chloroadenosine and the ganglioside mix AGF1 increased neurite elongation of striatal neurons after two days in vitro, but an inhibition of enhanced neurite outgrowth was observed when both substances were added together. Both laminin and fibronectin were not neuritogenic for postnatal striatal neurons under our culture conditions. These observations suggest that a factor other than the growth factors tested here is involved in the promotion of striatal neurite outgrowth in co-culture with myenteric plexus explants. In summary, adenosine (probably acting through the A2 subclass of the P1 purinoceptor) leads to increased striatal neurite outgrowth in co-culture with myenteric plexus and we propose that it does so either (1) by triggering the release of a neuritogenic factor, possibly from enteric glial cells, or (2) by acting synergistically with such a growth factor. Adenosine acts via P1 purinoceptors, which leads to changes in cyclic AMP, and the response to forskolin suggests that cyclic AMP is probably involved in the events leading to increased striatal neurite outgrowth.
authors.affiliation: Department of Anatomy and Developmental Biology, University College London, U.K.
authors.forename: V H
authors.initials: VH
authors.lastname: Höpker
authors.forename: M J
authors.initials: MJ
authors.lastname: Saffrey
authors.forename: G
authors.initials: G
authors.lastname: Burnstock
mesh_terms: D015762:2-Chloroadenosine / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000619:Aminohydrolases / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D005576:Colforsin / Q000494:pharmacology; D004347:Drug Interactions; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D005353:Fibronectins / Q000494:pharmacology; D005732:Gangliosides / Q000494:pharmacology; D006160:Guanosine Triphosphate / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D009197:Myenteric Plexus / Q000166:cytology* / Q000378:metabolism; D017072:Neostriatum / Q000166:cytology*; D009414:Nerve Growth Factors / Q000494:pharmacology; D016501:Neurites / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000166:cytology / Q000502:physiology* / Q000648:ultrastructure; D009479:Neuropeptides / Q000494:pharmacology; D020933:Neurotrophin 3; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D005353:Fibronectins; D005732:Gangliosides; D007797:Laminin; D009414:Nerve Growth Factors; D009479:Neuropeptides; D020933:Neurotrophin 3; D015762:2-Chloroadenosine; D005576:Colforsin; D012701:Serotonin; D013779:Tetrodotoxin; D005346:Fibroblast Growth Factors; C031433:8-(4-sulfophenyl)theophylline; D006160:Guanosine Triphosphate; D000255:Adenosine Triphosphate; D013806:Theophylline; D000619:Aminohydrolases; C018774:adenine deaminase; D000241:Adenosine